Stock Analysis
BrightSpring Health Services, Inc. Common StockBTSG
P/E 32.91×· 3Y range 30.02–76.01×· bottom 10% of history
Sector: Healthcare · Industry: Services-Home Health Care Services
AnalystsStrong Buy25 analystsP/E 32.9× sits at the 10th percentile of its 2.721309605293178-year history.
Cash covers 23% of debt · Q2 2026.
PMP Verdict
Mixed fundamentals, cheap valuation
Strengths
- Growth85
- Quality84
Risks
- Profitability43
Mixed business trading cheap — priced for skepticism.
Market context
-2.4% today· Z 1.7σ
Bull Case
- ✓Piotroski F-Score 7/9 — high earnings quality
- ✓Altman Z 3.6 — safe-zone balance sheet
- ✓ROE 17.8% — efficient capital deployment
- ✓Revenue CAGR 17.8% — durable top-line growth
- ✓P/E 32.9× at bottom 10% of 3-year history
What's happening with BTSG
Profile
Strong growth and earnings quality; moat and profitability lag behind.
How is each axis scored?
- Valuation67/100 · Moderate
- P/E vs own history (10th pct)25/25
- FCF yield (3.3%)12/25
- P/S (0.8x)25/25
- EV/EBIT (31.0x)5/25
- Growth85/100 · Strong
- Revenue CAGR (17.8%)20/25
- Net income CAGR (39.9%)25/25
- EPS CAGR 5Y (19.6%)20/25
- Fwd implied growth (25.0%)20/25
- Profitability43/100 · Weak
- ROIC (9.1%)12/25
- ROE (17.8%)20/25
- Net margin (2.5%)6/25
- Operating margin (3.1%)5/25
- Financial Health58/100 · Moderate
- Altman Z (3.64)25/25
- Current ratio (1.59)18/25
- Interest coverage (3.3x)10/25
- Net cash / debt (D/A 31%)5/25
- Quality84/100 · Strong
- Piotroski F (7/9)22/25
- Beneish M (-2.16)12/25
- FCF conversion (110%)25/25
- Margin stability (σ 1.2%)25/25
- Moat15/100 · Weak
- ROIC >12% years (0/5 yrs)0/25
- Median gross margin (14.8%)0/25
- FCF-positive years (3/5 yrs)10/25
- Worst-year net margin (worst -2.0%)5/25
Risk Flags
- ⚠3 loss-making years in recent history
About BrightSpring Health Services, Inc. Common Stock
BrightSpring Health Services Inc is a home and community-based healthcare services platform, focused on delivering complementary pharmacy and provider services to complex patients. Show more
Its platform delivers clinical services and pharmacy solutions across Medicare, Medicaid, and commercially insured populations. Its segments include Pharmacy Solutions, Provider Services, and others. It generates the majority of its revenue from the Pharmacy Solutions segment.
Headquarters: LOUISVILLE, KY · Employees: 23,500 · Website ↗
Price History
Weekly Candlestick Chart — up to 5Y
Key Metrics
Financial snapshot · Tap any metric for its definition and grade
TTM Snapshot
trailing twelve months · YoYValuation
67BP/E (TTM)32.9xC
Grade C: ExpensivePrice / TTM EPS (own statements) — vs own 3Y history: 30.0x–76.0x · 10th pct
P/FCF30.7xC
Grade C: ExpensivePrice / Free Cash Flow per share (Finnhub). Inverse of FCF yield — negative when FCF is negative
FCF Yield3.3%C
Grade C: LowTTM (OCF − CapEx) / Market Cap — vs own 3Y history: -8.4%–4.5% · 84th pct
P/S (TTM)0.84xA
Grade A: CheapPrice / TTM Revenue (own statements) — vs own 3Y history: 0.2x–1.1x · 85th pct
EV/EBIT31.0xD
Grade D: ExpensiveEnterprise value / TTM EBIT (D&A not in our data) — capital-structure neutral — vs own 3Y history: 27.1x–50.2x · 12th pct
EV/Sales1.0xA
Grade A: CheapEnterprise Value / TTM Revenue (Finnhub) — capital-structure neutral sales multiple
Forward P/E26.3xC
Grade C: ExpensivePrice / next-year EPS estimate — shows whether the TTM multiple is rich or just front-loading growth
P/B Ratio5.85xC
Grade C: ExpensivePrice to Book Value. Neg. equity = heavy buybacks
PEG Ratio1.32B
Grade B: FairFinnhub PEG — their P/E basis ÷ expected EPS growth. Suppressed when their P/E diverges >2× from our TTM P/E (different basis)
Dividend Yield—
TTM dividend yield (Finnhub) — annual dividends / price. None = no dividend; very high yield can signal distress
Payout Ratio—
Dividends / Net Income (Finnhub) — share of earnings paid out; >90% or negative = unsustainable
Profitability
43D+ROIC9.1%C
Grade C: AverageNOPAT (EBIT less ~21% tax) / invested capital (equity + debt − cash). Flagship quality metric — durable >15% signals a moat
ROE17.8%C
Grade C: AverageReturn on Equity. Neg. equity = heavy buybacks
ROA5.9%C
Grade C: AverageReturn on Assets (Finnhub) — Net Income / Total Assets; how efficiently assets produce profit
Net Margin2.5%D
Grade D: LowNet Income / Revenue
Operating Margin3.1%D
Grade D: LowTTM EBIT / TTM Revenue
Gross Margin12.4%D
Grade D: LowGross Profit / Revenue
FCF Margin2.8%D
Grade D: LowFCF / Revenue
True FCF Margin2.4%D
Grade D: LowTTM (OCF − CapEx − SBC) / TTM Revenue — SBC treated as a real cost
Growth
85ARevenue CAGR17.8%A
Grade A: HighCompound annual revenue growth (up to 5Y depending on data availability)
Net Income CAGR39.9%A
Grade A: HighCompound annual net income growth (up to 5Y depending on data availability)
EPS CAGR (5Y)19.6%A
Grade A: HighCompound annual EPS growth over up to 5Y of per-share earnings (own statements). Null when either endpoint EPS ≤ 0
Implied EPS Growth25.0%C
Grade C: MedAnalyst forward EPS (normalized basis) vs our GAAP TTM EPS — different bases, so extreme values usually mark cyclically depressed TTM earnings, not real growth
Dilution (5Y)+67.9%D
Grade D: DilutiveShare count change over 5Y
SBC / Net Income15.0%C
Grade C: MedStock-based comp/Net income. >30% = dilution risk
SBC / Revenue0.4%A
Grade A: LowTTM stock-based comp / TTM Revenue
Financial Health
58CAltman Z-Score3.64A
Grade A: SafeBankruptcy risk. >3 Safe, <1.8 Distress
Current Ratio1.59xC
Grade C: OkCurrent Assets/Liabilities
Quick Ratio1.19xA
Grade A: High(Current Assets − Inventory) / Current Liabilities (Finnhub) — stricter liquidity test, excludes inventory
Interest Coverage3.3xC
Grade C: OkEBIT/Interest. >10 Strong
Debt Repayment4.6yC
Grade C: AverageYears to repay net debt via FCF
Net Debt/EBIT4.1xD
Grade D: HighLeverage. <2x Low, >4x High
Debt/Equity1.16xC
Grade C: MedDebt / Equity: <1 Conservative, >2 Risky. Not meaningful with non-positive equity; shown as unavailable rather than low debt.
Cash / Debt0.23xD
Grade D: ThinCash covers how much of total debt. >1 = could repay all debt from cash
Quality
84APiotroski F-Score7/9A
Grade A: StrongFinancial strength 0–9. >7 Strong
Beneish M-Score-2.16C
Grade C: Gray zoneEarnings manipulation risk. < -2.22 Safe
FCF Conversion109.9%A
Grade A: StrongFCF / Net Income
Margin Stability1.2%A
Grade A: StableEBIT margin std deviation. Lower = stable
Capex / Revenue0.7%A
Grade A: Asset-lightTTM CapEx / TTM Revenue — high % = capital-hungry business
Asset Turnover2.33xA
Grade A: HighRevenue / Total Assets (Finnhub) — how efficiently the asset base generates sales
Insider Transactions
SEC Form 4 · 8 recordsP/S codes are the directional signal; grants, option exercises and tax withholding carry none. Form 4 doesn't flag 10b5-1 plans — scheduled sales may appear within open-market sells.
| Trade date | Insider | Transaction | Shares | Filed |
|---|---|---|---|---|
Greenwell Scott A. Filed | Greenwell Scott A. | Option exercise | -11973 | |
Greenwell Scott A. Filed | Greenwell Scott A. | SellOpen market sale | -15099 | |
Greenwell Scott A. Filed | Greenwell Scott A. | Option exercise | +12.0K | |
ROUSSEAU JON B Filed | ROUSSEAU JON B | Tax withholding | -56319 | |
Greenwell Scott A. Filed | Greenwell Scott A. | Tax withholding | -2487 |
Show 3 more filingsShow fewer filings
| Trade date | Insider | Transaction | Shares | Filed |
|---|---|---|---|---|
Shah Nigam H. Filed | Shah Nigam H. | Grant / award | +4.0K | |
Nalley Lisa A Filed | Nalley Lisa A | Option exercise | -35000 | |
Nalley Lisa A Filed | Nalley Lisa A | SellOpen market sale | -35000 |
Option exercise (M) rows report a derivative leg, not an open-market sale — a paired negative entry is the option position being consumed.
More metrics — Moat, Per Share, Balance Sheet, MarketHide additional metrics
Moat
15EROIC >12% Years0/5 yrsD
Grade D: WeakShare of completed fiscal years with ROIC > 12% — measures multi-year capital-return durability
Gross Margin (Med.)14.8%D
Grade D: WeakMedian annual gross margin across available fiscal years — pricing-power durability
FCF-Positive Years3/5 yrsD
Grade D: WeakShare of completed fiscal years with positive free cash flow
Net Margin Floor-2.0%D
Grade D: WeakWeakest annual net margin across completed fiscal years — recession/downcycle resilience
Per Share
EPS (TTM)$1.85
Own TTM net income / shares — same earnings basis as P/E
Cash / Share$2.79
Cash & short-term investments per share (Finnhub)
Book Value / Share$10.37
Shareholders' equity per share (Finnhub). Negative = accumulated losses / heavy buybacks
Balance Sheet
Total Debt$2.39B
Total debt obligations (short + long term)
Cash & Equiv.$550.38M
Cash and short-term investments
Net Debt$1.84B
Total Debt minus Cash. Negative = Net Cash position
Total Equity$2.06B
Shareholders' equity (book value)
Asset / Liability1.52xC
Grade C: AdequateTotal Assets / Total Liabilities
Market
Market Cap$12.04B
Current Market Capitalization
Beta1.89D
Grade D: High volatilityPrice sensitivity vs the market (Finnhub) — 1.0 moves with market, >1.2 amplifies swings
How grades work: each metric is graded A–D against fixed thresholds (tap a row for the meaning). Card grades map the pillar score to A+–E — a card grade is that pillar's own score, not an average of the rows shown.
Financials as of Jun 2026 · Ratio snapshot Oct 17, 2026
Key Insights: BrightSpring Health Services, Inc. Common Stock (BTSG)
BTSG is down 2.39% at the last close. BrightSpring Health Services, Inc. Common Stock meets 7 of 9 Piotroski F-Score criteria, placing its fundamental strength in the top tier of US-listed stocks. Altman Z-Score of 3.64 sits comfortably in the safe zone (≥ 2.99), indicating low bankruptcy risk.
- Revenue has compounded at roughly 18% annually, with net income growing about 40% per year — a strong growth profile.
- Takes ~4.6 years to repay net debt from free cash flow.
- BrightSpring Health Services, Inc. Common Stock posted a net loss in 3 of 5 available completed fiscal years (2021–2025).
See how BTSG ranks on the Capex Tracker — top 50 capital spenders compared.
Recent Market Moves
See all BTSG moves →| Date | Session | Price | Move | Z-Score |
|---|---|---|---|---|
| Oct 15 | After-hours | 61.40 | -3.08% | -2.22 |
| Oct 2 | Regular | 60.30 | +5.30% | 2.42 |
Frequently Asked Questions about BTSG
What is the current BrightSpring Health Services, Inc. Common Stock (BTSG) stock price?
BTSG is trading at $60.87 at the last market close, down 2.39% on the session. PreMarketPrice tracks BTSG pre-market, intraday and after-hours prices.
Is BTSG stock a buy right now?
PreMarketPrice's quantitative model rates BrightSpring Health Services, Inc. Common Stock's financial health at 58/100. This is a data-driven snapshot of fundamentals, not investment advice.
Is BTSG stock overvalued?
BrightSpring Health Services, Inc. Common Stock trades at a trailing P/E of 32.9 and our valuation score rates it 67/100 (higher = cheaper vs. its own history). See the Valuation History and Key Metrics sections for forward P/E, EV/EBITDA and PEG context.
When does BrightSpring Health Services, Inc. Common Stock report earnings?
No confirmed earnings date is currently scheduled for BTSG. The Earnings section lists recent reports and updates as dates are announced.
What sector does BrightSpring Health Services, Inc. Common Stock operate in?
BrightSpring Health Services, Inc. Common Stock operates in the Healthcare sector, within the Services-Home Health Care Services industry. The Related Stocks section lists sector peers for comparison.
What does BrightSpring Health Services, Inc. Common Stock do?
BrightSpring Health Services Inc is a home and community-based healthcare services platform, focused on delivering complementary pharmacy and provider services to complex patients.
About BrightSpring Health Services, Inc. Common Stock (BTSG) Stock
BrightSpring Health Services, Inc. Common Stock (BTSG) is a US-listed stock operating in the Healthcare sector, specifically the Services-Home Health Care Services industry. As of the latest update, BrightSpring Health Services, Inc. Common Stock is trading at $60.87, down 2.39% on the day with a market capitalization of $12.0 billion. The financial health score for BTSG is 58/100, which indicates moderate financial strength based on profitability, leverage, liquidity, and growth metrics. This page provides real-time pre-market pricing, earnings calendar, financial health analysis, and valuation metrics for BTSG stock.
BTSG Stock Analysis & Key Metrics
On PreMarketPrice, you can track BrightSpring Health Services, Inc. Common Stock (BTSG) across multiple dimensions:
- Pre-market price & movement: Real-time BTSG stock price with percentage change, updated continuously during pre-market and regular trading hours.
- Valuation & P/E history: Historical P/E, P/S, and P/B ratios for BTSG with trend analysis and normalized valuation multiples.
- Financial statements: Revenue, net income, assets, liabilities, and equity for BrightSpring Health Services, Inc. Common Stock across multiple reporting periods.
- Financial health score: A composite score of 58/100 based on Altman Z-Score, Piotroski F-Score, profitability, and leverage metrics for BTSG.
- Sector peers: Compare BTSG against 4 other healthcare stocks on key financial metrics.
Is BTSG a Good Stock to Buy?
This page provides data-driven analysis to help you evaluate BrightSpring Health Services, Inc. Common Stock (BTSG) as an investment. The financial health score of 58/100 suggests moderate financial fundamentals. Valuation metrics show whether the stock is trading above or below its historical average.However, this is not financial advice — always do your own research before investing.
Data on this page is sourced from real-time market feeds, Polygon.io, and Finnhub.BrightSpring Health Services, Inc. Common Stock (BTSG) trades on NYSE/NASDAQ. Pre-market trading occurs 4:00 AM – 9:30 AM ET. Regular market hours are 9:30 AM – 4:00 PM ET.